What's Going On With Moderna Stock Friday?
Portfolio Pulse from Dylan Berman
Moderna, Inc. (NASDAQ:MRNA) stock is trending on Friday following the European Medicines Agency’s positive opinion on its RSV vaccine, mRNA-1345, for adults aged 60 and older. The vaccine showed an efficacy rate of 83.7% in a Phase 3 trial. Analysts have recently adjusted their price targets for Moderna.
June 28, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's stock is trending due to the European Medicines Agency’s positive opinion on its RSV vaccine, mRNA-1345, for adults aged 60 and older. The vaccine showed an efficacy rate of 83.7% in a Phase 3 trial. Analysts have recently adjusted their price targets for Moderna.
The positive opinion from the European Medicines Agency is a significant regulatory milestone for Moderna's RSV vaccine, which could lead to increased sales and revenue. The high efficacy rate from the Phase 3 trial further supports the vaccine's potential. Analyst price target adjustments indicate mixed sentiment but overall positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100